Mansoor Raza Mirza, MD, discusses the safety profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.
Mansoor Raza Mirza, MD, medical director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit and chief oncologist within the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the safety profile of niraparib (Zejula) in combination with bevacizumab (Avastin) in platinum-sensitive recurrent ovarian cancer.
During the 2020 ASCO Virtual Scientific Program, final analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trialdemonstrated continued, statistically significant activity with the combination compared with niraparib alone in this patient population.
Notably, no new safety signals were observed with the regimen, says Mirza. Some patients experienced adverse effects such as hypertension and proteinuria, but they were not unexpected in this setting.
Moreover, no deterioration in quality of life according to patient-reported outcomes was reported with the combination versus niraparib alone, Mirza concludes.